SITAGLYN M IR 50/1000 TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve glycaemic control (blood sugar) along with diet and exercise; used when metformin alone is inadequate or as part of combination therapy.

Sitagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1/GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin decreases hepatic glucose production and improves insulin sensitivity, lowering blood glucose without usually causing hypoglycaemia when used alone.

Oral tablet. Take exactly as prescribed, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew unless advised. Regularly monitor blood glucose; follow diet and exercise advice.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection, nasopharyngitis

Prescription-only anti-diabetic. Risk of lactic acidosis with metformin—higher in kidney impairment, dehydration, severe infection, shock, liver disease, heavy alcohol use; stop and seek urgent care for rapid breathing, severe weakness, muscle pain, unusual sleepiness. Contraindicated in severe renal impairment; assess eGFR before start and periodically. Hold metformin before/at time of iodinated contrast procedures and restart after renal function is re-evaluated. Sitagliptin may rarely cause pancreatitis (severe persistent abdominal pain), severe joint pain, hypersensitivity reactions; use caution in history of pancreatitis. Hypoglycaemia risk increases if used with insulin or sulfonylureas. Use caution in elderly and in conditions causing hypoxia.